A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
DM199 (recombinant human tissue kallikrein-1) is a new investigational compound that may
eventually be used for the treatment of Diabetes Mellitus Type 2. This is the first time that
this compound is being given to humans.
The purpose of the study is to investigate to what extent DM199 is safe and tolerated.
Further, it will be investigated how quickly and to what extent DM99 is absorbed and
eliminated from the body (this is called pharmacokinetics). In addition, the effect of the
compound on the body will be investigated (this is called pharmacodynamics).
This study is not intended to improve anyone's health, but is necessary for the further
development of DM199.
The study consists of 4 parts. Each part (A, B, C and D) will consist of one or several
periods. The research will be conducted in healthy male and female volunteers (Part A and C)
and in male and female type 2 diabetes mellitus patients (Part B and D).